• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Maternal Outcomes and COVID-19: Results from a Large US-Based Cohort

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Jering et al. (JAMA Internal Medicine, 2021) compared the clinical characteristics and outcomes of hospitalized women who gave birth with and without COVID-19

METHODS:

  • Cohort study
  • Data source
    • Premier Healthcare Database | Includes ~20% of all US hospitalizations
  • Participants
    • Women giving birth who were discharged between April 1 and November 23, 2020
  • Study design
    • Characteristics included: Race/ethnicity (self-reported) | COVID-19 status | Comorbidities | In-hospital outcomes 
    • Associations between COVID-19 and in-hospital outcomes were examined using propensity score-adjusted regression
    • Logistic regression analysis used to determine risk factors for in-hospital death or mechanical ventilation

RESULTS:

  • 406,446 women admitted for delivery
    • Incidence of COVID-19: 1.6% (6380 women)
  • Compared to pregnant women without COVID-19, women with COVID-19 were more likely to be
    • Black and/or Hispanic
    • Diabetic
    • Obese
  • Maternal outcomes
    • Discharged home: 98.9%
    • Intensive care: 3.3%
    • Mechanical ventilation: 1.3%
    • Died in the hospital: 0.1%
  • In-hospital mortality was overall low but still significantly higher in pregnant women with COVID-19
    • With COVID-19: 141 deaths/100,000 women (95% CI, 65 to 268)
    • Without: 5.0 deaths/100,000 women (95% CI, 3.1 to 7.7)
  • Rates of myocardial infarction and venous thromboembolism (VTE) were higher in the women with COVID-19 (P < 0.001)
    • Myocardial infarction
      • With COVID-19: 0.1%
      • Without: 0.004%
    • VTE
      • With COVID-19: 0.2%
      • Without: 0.1%
  • COVID-19 was associated with higher odds of
    • Preeclampsia
      • Adjusted odds ratio (aOR) 1.21 (95% CI, 1.11 to 1.33)
    • Preterm birth
      • aOR 1.17 (95% CI, 1.06 to 1.29)
  • COVID-19 was not associated with higher odds of stillbirth
    • aOR 1.23 (95% CI, 0.87 to 1.75)
  • Use of the following was higher in women who gave birth with COVID-19
    • Chest imaging
    • Intensive care treatment
    • Mechanical ventilation
  • The following were associated with higher odds of mechanical ventilation or in-hospital death among women with COVID-19
    • Age: OR 1.91 (95% CI, 1.31 to 2.77) per 10 years
    • Morbid obesity: OR 3.85 (95% CI, 2.05 to 7.21)
    • Diabetes: OR 4.51 (95% CI, 2.10 to 9.70)
    • Kidney disease: OR 21.57 (95% CI, 7.73 to 60.10)
    • Eclampsia: OR 116.1 (95% CI, 22.91 to 588.50)
    • Thrombotic events: OR 45.10 (95% CI, 17.13 to 118.8)
    • Stillbirth: OR 7.88 (95% CI, 2.39 to 25.98)

CONCLUSION:

  • In this large population of US women giving birth, mortality and adverse events were rare, even with COVID-19
  • However, the risk of in-hospital death, VTE and preeclampsia was significantly higher in women with COVID-19
  • The authors conclude

As studies investigating therapies for COVID-19 have largely excluded pregnant women, the data also underscore the importance of including this population in clinical trials of treatments and vaccines

Learn More – Primary Sources:

Clinical Characteristics and Outcomes of Hospitalized Women Giving Birth With and Without COVID-19

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

The UKOSS COVID-19 Pregnancy Registry: Update on 427 Patients Admitted to Hospital
Universal Screening: What Percent of Women Admitted to L&D are Positive for SARS-CoV-2?
ICU Admission for COVID-19 and Maternal Outcomes

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site